Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Earnings Data
Report Date
Nov 04, 2025Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.43Last Year’s EPS
0.42Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Bio-Techne's earnings call highlighted solid performance in the biopharma sector and strategic moves to enhance profitability, but also underscored challenges in academia and uncertainties in the biotech funding environment. The divestiture of Exosome Diagnostics is expected to improve margins, while potential tariff impacts and NIH funding uncertainties pose risks.Company Guidance
Solid Quarterly Performance
Bio-Techne delivered 3% organic revenue growth in the fourth quarter of Fiscal Year 2025, driven by strong demand in the biopharma end markets, particularly among large pharma customers.
Profitability Focus
The company achieved an adjusted operating margin of 32% for the quarter, emphasizing operational efficiencies and a disciplined approach to investing for future growth.
Strategic Divestiture
Bio-Techne announced the divestiture of its Exosome Diagnostics business, expected to close in the first quarter of fiscal 2026, allowing the company to focus on its core growth pillars and improve operating margins.
Protein Sciences Segment Growth
The Protein Sciences segment grew 4% in the quarter with strong demand for proteomic analytical tools and cell therapy workflow solutions. The segment achieved a 5% revenue increase for the full fiscal year.
Geographic Performance
China delivered a positive surprise with low double-digit growth in the quarter, indicating stabilization and a gradual return to modest growth in the region.
Cell Therapy Solutions Demand
The demand for Bio-Techne's GMP reagents portfolio grew 20% in Q4 and exceeded 30% growth for the full fiscal year, supported by over 550 customers.
TECH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TECH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $54.56 | $49.80 | -8.72% |
May 07, 2025 | $47.57 | $48.60 | +2.17% |
Feb 05, 2025 | $72.24 | $74.92 | +3.71% |
Oct 30, 2024 | $70.36 | $75.61 | +7.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Techne (TECH) report earnings?
Bio-Techne (TECH) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).
What is Bio-Techne (TECH) earnings time?
Bio-Techne (TECH) earnings time is at Nov 04, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TECH EPS forecast?
TECH EPS forecast for the fiscal quarter 2026 (Q1) is 0.43.